Sign in

Gastric and oesophageal cancer: trials that stopped early

Trials on gastric and oesophageal cancer that stopped early, each with the reason the sponsor wrote in the registry, quoted word for word. Next to them: finished trials whose registry record links a result paper.

Stopped early

131 stopped trials give a reason in the registry, latest registry update first. 5 more give no reason and are not listed.

  1. Suspended

    Endoscopic Prevention of Esophageal Cancer at Tenwek Hospital

    Reason given in the registry

    “Medtronic owns Covidien \& closed study 11/18/15. Will reapply through Medtronic.”

    Quoted unchanged from ClinicalTrials.gov; record updated 11 Dec 2023.

    Ended
    Jul 2024
    Run by
    Tenwek Hospital
    Registry record
    NCT02146508
  2. Withdrawn

    Evaluation of the Autonomic Nervous System in Patients Undergoing Esophagectomy for Cancer

    Reason given in the registry

    “Due to a lack of staff in the department, no inclusion could be realized.”

    Quoted unchanged from ClinicalTrials.gov; record updated 24 Nov 2023.

    Ended
    Sept 2024
    Run by
    Centre Hospitalier Universitaire de Saint Etienne
    Registry record
    NCT04835987
  3. Withdrawn

    SOX-based CRT for Esophageal Cancer.

    Reason given in the registry

    “No eligible patients enrolled. We have to withdraw the trial.”

    Quoted unchanged from ClinicalTrials.gov; record updated 21 Sept 2023.

    Ended
    Dec 2023
    Phase
    Phase 1/2
    Run by
    Zhejiang Provincial People's Hospital
    Registry record
    NCT03991104
  4. Withdrawn

    EP0057 in Combination With Olaparib in Relapsed Advanced Gastric Cancer and Small Cell Lung Cancer

    Reason given in the registry

    “Futility analysis decision to terminate EP0057 compound and all Ellipses sponsored studies involving EP0057.”

    Quoted unchanged from ClinicalTrials.gov; record updated 12 Jun 2023.

    Ended
    Dec 2024
    Phase
    Phase 2
    Run by
    Ellipses Pharma
    Registry record
    NCT05411679
  5. Suspended

    Safety and Activity Study of HER2-Targeted Dual Switch CAR-T Cells (BPX-603) in Subjects With HER2-Positive Solid Tumors

    Reason given in the registry

    “Due to a Dose Limiting Toxicity in another sister trial with same technology.”

    Quoted unchanged from ClinicalTrials.gov; record updated 20 Apr 2023.

    Phase
    Phase 1
    Run by
    Bellicum Pharmaceuticals
    Registry record
    NCT04650451
  6. Withdrawn

    Gastrointestinal Anastomosis Using MonoPlus® Suture

    Reason given in the registry

    “The GASTROMO study has been stopped early before enrolling its first patient because the results of our primary endpoint would have been inconsistent. The variability of the leakage rate between all anastomosis included in the study was overly high.”

    Quoted unchanged from ClinicalTrials.gov; record updated 5 Apr 2023.

    Ended
    Dec 2023
    Run by
    Aesculap AG
    Registry record
    NCT04811833
  7. Withdrawn

    ChemoRadiation And Tislelizumab for Esophageal/EGJ Cancer

    Reason given in the registry

    “Funding unavailable.”

    Quoted unchanged from ClinicalTrials.gov; record updated 8 Nov 2022.

    Phase
    Phase 2
    Run by
    Zhonglin Hao
    Registry record
    NCT05245760
  8. Withdrawn

    Pilot Study of Antiviral Treatment in Combination With Low-dose Gemcitabine in EBV-associated Gastric Cancer (EBVaGC)

    Reason given in the registry

    “Research withdrawal before patient registration due to difficulty in continuing research”

    Quoted unchanged from ClinicalTrials.gov; record updated 1 Nov 2022.

    Ended
    Jul 2024
    Run by
    Samsung Medical Center
    Registry record
    NCT05431244
  9. Withdrawn

    LS301 Uptake in Tumors of Patients Undergoing Liver, Pancreas, or Gastric Surgery

    Reason given in the registry

    “One of the investigators is leaving the University.”

    Quoted unchanged from ClinicalTrials.gov; record updated 9 Dec 2021.

    Ended
    Dec 2023
    Phase
    Phase 1/2
    Run by
    Washington University School of Medicine
    Registry record
    NCT04105062
  10. Withdrawn

    An Investigational Immuno-therapy Study of Relatlimab Plus Nivolumab Compared to Various Standard-of-Care Therapies in Previously Treated Participants With Recurrent, Advanced or Metastatic Gastric Cancer or Gastroesophageal Junction Adenocarcinoma

    Reason given in the registry

    “Replaced it with another clinical trial”

    Quoted unchanged from ClinicalTrials.gov; record updated 19 May 2020.

    Ended
    Sept 2024
    Phase
    Phase 2
    Run by
    Bristol-Myers Squibb
    Registry record
    NCT03704077
  11. Withdrawn

    Collection of Biospecimen & Clinical Information in Patients w/ Gastrointestinal Cancers

    Reason given in the registry

    “Change in research focus”

    Quoted unchanged from ClinicalTrials.gov; record updated 28 May 2012.

    Run by
    Stanford University
    Registry record
    NCT01031056

Sources: ClinicalTrials.gov and the EU Clinical Trials Register. Status, reason, dates and result links are registry fields, shown as the registry gives them.